Trypsin-Chymotrypsin
Phase 3Small molecule
Trypsin-Chymotrypsin is one of 7 small molecule programs targeting Symptomatic Irreversible Pulpitis. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in Symptomatic Irreversible Pulpitis
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Approved
Trypsin-Chymotrypsin
DDow University of Health Sciences
Phase 3
Cataflam
NovartisPreclinical
Ultram
WWim Janssens
Preclinical
Naproxen Sodium
BayerPreclinical
Diclofenac Potassium Tab.
CCairo University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Endodontic Treatment1 trial
Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain
Recruiting·—·Phase 4·NCT06562816·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trypsin-Chymotrypsin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details